@article{0fb5e3e6e0634ccfb3c26ff7d505df99,
title = "Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study",
keywords = "IBCL, PI3K., Phase II, TIDAL, Clinical trial, Follicular lymphoma, Inhibitor, Zandelisib",
author = "T Phillips and W Jurczak and V Ribrag and K Linton and GP Collin and J Lop{\'e}z-Jimen{\'e}z and N Reddy and A Mengarelli and G Musuraca and O Sheehy and WM Xu and M Azoulay and RG Ghalie and PL Zinzani and Zelenetz, {Andrew D.}",
year = "2022",
month = oct,
language = "English",
volume = "22",
pages = "S387--S388",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Elsevier BV",
}
